“…11 However, imiquimod remains an off-label indication for melanoma because of the lack of randomized, prospective trials demonstrating its efficacy compared with conventional surgery. 7,13,[17][18][19][20] A thorough discussion of risks and benefits is necessary so that patients/families understand the limitations of treatment with imiquimod over standard surgical resection, including the risk of missing or undertreating invasive melanoma, local recurrence caused by lack of histologic margin control, and absence of long-term randomized controlled trials or comparative studies. 11 Close follow-up is recommended in patients treated with imiquimod, along with a low threshold to perform ''scouting'' biopsies after treatment and biopsy of any recurrent pigmentation in imiquimod-treated sites.…”